Based on the structural elements of bioactive 3-substituted indoles, a new series of indole–thiosemicarbazone hybrid derivatives were designed, synthesized, and well-characterized using different spectral techniques. The intended scaffolds were screened for their in vitro anti-proliferative activities against breast cancer (MCF-7), lung cancer (A-549), and liver cancer (Hep-G2) cell lines, as well as their anti-oxidant properties. Cytotoxicity studies revealed that compound 6n was the most potent, at least threefold more potent than the commercially available reference drug etoposide, against A-549. In addition, morphological analysis by the acridine orange/ethidium bromide double staining test and flow cytometry analysis confirmed induction of apoptosis in the A-549 cells by compound 6n. In order to validate the experimental results, molecular studies were performed to achieve the possible binding interactions of the most potent compound (6n) and colchicine with tubulin as well as ANP with ATPase domain of topoisomerase IIα active sites. Moreover, the radical scavenging potential of the final derivatives was found to be excellent with the range of 0.015–0.630 µM, comparable to the standard ascorbic acid (0.655 µM).
基于
生物活性3-取代
吲哚的结构元素,设计、合成了新一系列
吲哚-缩
氨硫脲杂化衍
生物,并利用不同光谱技术对其进行了很好的表征。对这些预期的支架结构进行了体外抗增殖活性筛选,针对乳腺癌(MCF-7)、肺癌(A-549)和肝癌(Hep-G2)
细胞系,以及它们的抗氧化性能。细胞毒性研究表明,化合物6n对A-549的活性最强,至少是市售参考药物
依托泊苷的三倍。此外,通过
吖啶橙/
溴化乙锭双重染色试验和流式细胞术分析,确认化合物6n诱导A-549细胞凋亡。为了验证实验结果,进行了分子研究,以实现最强化合物(6n)和
秋水仙碱与微管蛋白的可能结合相互作用,以及ANP与拓扑异构酶IIα的
ATP酶域活性位点的相互作用。此外,最终衍
生物的自由基清除潜力非常出色,范围为0.015-0.630 µM,与标准
抗坏血酸(0.655 µM)相当。